ENJAYMO is an infusion that is given weekly for the first two weeks, with administration every two weeks thereafter.
ENJAYMO is given through a vein by intravenous (IV) infusion, usually over 1 to 2 hours.
After the first infusion, you should be monitored for allergic reactions for at least 2 hours. After future infusions, you should be monitored for at least 1 hour for allergic reactions.
The infusion process is an essential part of your treatment plan. This process can vary from patient to patient, so it's important to ask your healthcare provider what the process may look like for you.
ENJAYMO can be infused at:
To find out which option is suitable for you, speak with your doctor. Your infusion location options may depend on your health insurance coverage.
Use our Doctor Discussion Guide to have a productive conversation with your doctor or healthcare team to see if ENJAYMO is right for you.
Whether you're taking ENJAYMO or interested in learning more, sign up to receive additional information, resources, and helpful tools to support you on your journey with Cold Agglutinin Disease.
Sign Up NowENJAYMO is a prescription medicine used to treat the breakdown of red blood cells (hemolysis) in adults with Cold Agglutinin Disease (CAD). It is not known if ENJAYMO is safe and effective in children.
ENJAYMO is a prescription medicine used to decrease the need for red blood cell transfusion due to the breakdown of red blood cells (hemolysis) in adults with cold agglutinin disease (CAD).
It is not known if ENJAYMO is safe and effective in children.
Do not receive ENJAYMO if you are allergic to sutimlimab-jome or any of the ingredients in ENJAYMO.
ENJAYMO can cause serious side effects, including:
Vaccinations may reduce the risk of these infections, but do not prevent all infections. Call your healthcare provider or get medical help right away if you get any new signs and symptoms of an infection, including:
The most common side effects of ENJAYMO include:
These are not all the possible side effects of ENJAYMO. Call your doctor for medical advice about side effects.
Before receiving ENJAYMO, tell your healthcare provider about all of your medical conditions, including if you:
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
Please see Full Prescribing Information, including Medication Guide.
ENJAYMO is a prescription medicine used to decrease the need for red blood cell transfusion due to the breakdown of red blood cells (hemolysis) in adults with cold agglutinin disease (CAD).
It is not known if ENJAYMO is safe and effective in children.
ENJAYMO is a prescription medicine used to decrease the need for red blood cell transfusion due to the breakdown of red blood cells (hemolysis) in adults with cold agglutinin disease (CAD).
It is not known if ENJAYMO is safe and effective in children.
Do not receive ENJAYMO if you are allergic to sutimlimab-jome or any of the ingredients in ENJAYMO.
ENJAYMO can cause serious side effects, including:
Vaccinations may reduce the risk of these infections, but do not prevent all infections. Call your healthcare provider or get medical help right away if you get any new signs and symptoms of an infection, including:
The most common side effects of ENJAYMO include:
These are not all the possible side effects of ENJAYMO. Call your doctor for medical advice about side effects.
Before receiving ENJAYMO, tell your healthcare provider about all of your medical conditions, including if you:
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
Please see Full Prescribing Information, including Medication Guide.